257 related articles for article (PubMed ID: 35359944)
1. B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma.
Minici C; Testoni S; Della-Torre E
Front Immunol; 2022; 13():867902. PubMed ID: 35359944
[TBL] [Abstract][Full Text] [Related]
2. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.
Minici C; Rigamonti E; Lanzillotta M; Monno A; Rovati L; Maehara T; Kaneko N; Deshpande V; Protti MP; De Monte L; Scielzo C; Crippa S; Arcidiacono PG; Dugnani E; Piemonti L; Falconi M; Pillai S; Manfredi AA; Della-Torre E
Oncoimmunology; 2020 Jul; 9(1):1794359. PubMed ID: 32923157
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
4. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression.
Takahashi R; Macchini M; Sunagawa M; Jiang Z; Tanaka T; Valenti G; Renz BW; White RA; Hayakawa Y; Westphalen CB; Tailor Y; Iuga AC; Gonda TA; Genkinger J; Olive KP; Wang TC
Gut; 2021 Feb; 70(2):330-341. PubMed ID: 32393543
[TBL] [Abstract][Full Text] [Related]
6. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
[TBL] [Abstract][Full Text] [Related]
7. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
8. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
9. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
10. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
11. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
12. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.
Grage-Griebenow E; Jerg E; Gorys A; Wicklein D; Wesch D; Freitag-Wolf S; Goebel L; Vogel I; Becker T; Ebsen M; Röcken C; Altevogt P; Schumacher U; Schäfer H; Sebens S
Mol Oncol; 2014 Jul; 8(5):982-97. PubMed ID: 24746181
[TBL] [Abstract][Full Text] [Related]
13. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
Hiraoka N; Onozato K; Kosuge T; Hirohashi S
Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
16. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
18. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
19. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
Li TJ; Jin KZ; Li H; Ye LY; Li PC; Jiang B; Lin X; Liao ZY; Zhang HR; Shi SM; Lin MX; Fei QL; Xiao ZW; Xu HX; Liu L; Yu XJ; Wu WD
Cancer Lett; 2022 Apr; 530():142-155. PubMed ID: 35077803
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
